GeneDx (WGS) Q2 2026 Earnings Call Transcript
GeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.
How this was made
The 30-second read
Why it matters
Traders can update models around Q3 and full-year revenue guidance, profitability timing, and the sustainability of ARR given payer coverage and collection-rate variability. Whole-genome production costs nearly doubling is a key margin risk to monitor.
Market read
The call provides actionable guidance and KPI changes (payer coverage, collection rate, WGS cost) that can drive near-term estimate revisions and positioning into Q3.
What to watch
Revenue recognition lags collections by a couple of quarters, so near-term financials may not fully reflect current payer-policy improvements or operational changes.
Background
The piece is a GeneDx (WGS) Q2 2026 earnings call transcript summarizing financial results, operational KPIs, and updated guidance.
Market effects
Highlights payer-coverage execution and revenue-cycle management as key differentiators for genomic testing labs, with WGS cost inflation as a near-term margin headwind.
Medicaid expansion to 39 states (including Mississippi) signals broader US reimbursement tailwinds for genomic testing demand.
Primarily US reimbursement and payer policy dynamics; limited direct global read-through.
Counterpoint
The outpatient genome collection rate fell 11 points year over year, implying ARR durability may be more fragile than the headline revenue growth suggests.
Key entities
- companyGeneDx
Genomic testing provider reporting Q2 2026 results and issuing Q3 and full-year 2026 guidance, with emphasis on whole genome sequencing transition and payer coverage.
- executiveKatherine Stueland
CEO discussing market development strategy and how unpaid volume can accrete revenue as coverage expands.
- executiveKevin Feeley
CFO focusing on revenue cycle execution, collection-rate variability, and timing of revenue recognition.
- executiveMark Gardner
President outlining operational levers to improve reimbursement and revenue-cycle performance.
- counterpartyCarelon
Payer/coverage policy provider cited as driving commercial genome coverage expansion.
